SG11201900634VA - Chimeric antigen receptor - Google Patents
Chimeric antigen receptorInfo
- Publication number
- SG11201900634VA SG11201900634VA SG11201900634VA SG11201900634VA SG11201900634VA SG 11201900634V A SG11201900634V A SG 11201900634VA SG 11201900634V A SG11201900634V A SG 11201900634VA SG 11201900634V A SG11201900634V A SG 11201900634VA SG 11201900634V A SG11201900634V A SG 11201900634VA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- tower
- rule
- temasek
- tessa
- Prior art date
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 title abstract 5
- 239000003814 drug Substances 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 230000000139 costimulatory effect Effects 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000003834 intracellular effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the structure of the chimeric antigen receptor [CAR]
- A61K2239/22—Intracellular domain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/53—Liver
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001166—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464474—Proteoglycans, e.g. glypican, brevican or CSPG4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/303—Liver or Pancreas
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Hospice & Palliative Care (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 01 February 2018 (01.02.2018) WIPO I PCT °Ens °nolo omm Oil mo 0II1111111 ow (10) International Publication Number WO 2018/019772 Al (51) International Patent Classification: A61K 39/00 (2006.01) Cl 2N 5/0783 (2010.01) C07K 16/30 (2006.01) (21) International Application Number: PCT/EP2017/068654 (22) International Filing Date: 24 July 2017 (24.07.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/366,729 26 July 2016 (26.07.2016) US 62/366,731 26 July 2016 (26.07.2016) US (71) Applicant: TESSA THERAPEUTICS PTE. LTD. [SG/SG]; 8 Temasek Boulevard #24-02, Suntec Tower Three, Singapore 038988 (SG). (71) Applicant (for LS only): RICHARD IAN CLEGG [GB/GB]; City Tower, 40 Basinghall Street, London Greater London EC2V 5DE (GB). (72) Inventors: CONNOLLY, John Edward; c/o Tessa Ther- apeutics Pte. Ltd., 8 Temasek Boulevard #24-02, Suntec Tower Three, Singapore 038988 (SG). VU, Dang L.; c/o Tessa Therapeutics Pte. Ltd., 8 Temasek Boulevard #24-02, Suntec Tower Three, Singapore 038988 (SG). (74) Agent: CLEGG, Richard et al.; Mewburn Ellis LLP, City Tower, 40 Basinghall Street, London Greater London EC2V 5DE (GB). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, (54) Title: CHIMERIC ANTIGEN RECEPTOR (57) : Chimeric Antigen Receptors (CARs) comprising a costimulatory sequence which is, or which is derived from, the intracellular domain of CD226, or a fragment thereof, are disclosed. Also disclosed are compositions comprising such CARs, and uses and methods using the same. Figure 'IA W O 20 18/0 1977 2 Al Figure 113 [Continued on next page] WO 2018/019772 Al IMEDIMOM0101011MERIONIMOHMOHOMOIREM TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — of inventorship (Rule 4.17(iv)) Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) with sequence listing part of description (Rule 5.2(a))
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662366729P | 2016-07-26 | 2016-07-26 | |
US201662366731P | 2016-07-26 | 2016-07-26 | |
PCT/EP2017/068654 WO2018019772A1 (en) | 2016-07-26 | 2017-07-24 | Chimeric antigen receptor |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201900634VA true SG11201900634VA (en) | 2019-02-27 |
Family
ID=59569287
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201900634VA SG11201900634VA (en) | 2016-07-26 | 2017-07-24 | Chimeric antigen receptor |
Country Status (10)
Country | Link |
---|---|
US (1) | US20190262397A1 (en) |
EP (1) | EP3490589A1 (en) |
JP (1) | JP2019530431A (en) |
KR (1) | KR20190038567A (en) |
CN (1) | CN110035768A (en) |
AU (1) | AU2017301826A1 (en) |
CA (1) | CA3031846A1 (en) |
SG (1) | SG11201900634VA (en) |
TW (1) | TW201806969A (en) |
WO (1) | WO2018019772A1 (en) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018018958A1 (en) * | 2016-04-22 | 2018-02-01 | Carsgen Therapeutics Co., Ltd. | Compositions and methods of cellular immunotherapy |
CN110573528B (en) * | 2017-03-29 | 2023-06-09 | 豪夫迈·罗氏有限公司 | Bispecific antigen binding molecules to costimulatory TNF receptors |
CN108913709A (en) * | 2018-06-26 | 2018-11-30 | 山东兴瑞生物科技有限公司 | For treating the preparation method of the nucleic acid of HCC, preparation method, CAR-T cell and cell with the nucleic acid |
WO2020017479A1 (en) * | 2018-07-17 | 2020-01-23 | ノイルイミューン・バイオテック株式会社 | Anti-gpc3 single-chain antibody-containing car |
EP3860716A2 (en) * | 2018-10-01 | 2021-08-11 | Adicet Bio Inc. | Compositions and methods regarding engineered and non-engineered gamma-delta -t cells for treatment of solid tumors |
CN112300288B (en) * | 2019-07-29 | 2022-08-02 | 济南赛尔生物科技股份有限公司 | Chimeric antigen receptor CAR of CIK cell and application thereof |
CN114901294A (en) * | 2019-09-10 | 2022-08-12 | 赛通免疫治疗公司 | Bispecific antibody CAR cellular immunotherapy |
EP4041759A4 (en) * | 2019-10-07 | 2023-12-20 | Fate Therapeutics, Inc. | Enhanced chimeric antigen receptor for immune effector cell engineering and use thereof |
CN110790842B (en) * | 2019-11-25 | 2021-03-30 | 贵州康钦承平生物科技有限公司 | FasL-CAR fusion protein, T cell for expressing fusion protein, and preparation method and application thereof |
US20230055143A1 (en) * | 2019-12-20 | 2023-02-23 | Medimmune, Llc | Compositions and Methods of Treating Cancer with Chimeric Antigen Receptors Targeting Glypican 3 |
CN113087806B (en) * | 2019-12-31 | 2022-09-06 | 华东师范大学 | Novel CAR-T cells targeting multiple tumors, and preparation and methods thereof |
WO2021186397A1 (en) * | 2020-03-18 | 2021-09-23 | Eutilex Co., Ltd. | Gpc3 car-t cell compositions and methods of making and using the same |
WO2021186395A1 (en) * | 2020-03-18 | 2021-09-23 | Eutilex Co., Ltd. | Gpc3 car- t cells secreting il-18 and methods of making and using the same |
CN112225822B (en) * | 2020-12-14 | 2021-03-23 | 北京基因启明生物科技有限公司 | CAR-iNKT with high amplification, survival ability and tumor killing effect and application thereof |
WO2023024084A1 (en) * | 2021-08-27 | 2023-03-02 | 原启生物科技(上海)有限责任公司 | Chimeric antigen receptor and use thereof |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004106383A1 (en) | 2003-05-31 | 2004-12-09 | Micromet Ag | Pharmaceutical composition comprising a bispecific antibody for epcam |
US20050180979A1 (en) | 2004-02-13 | 2005-08-18 | Micromet Ag | Anti-EpCAM immunoglobulins |
MY145073A (en) | 2004-07-09 | 2011-12-15 | Chugai Pharmaceutical Co Ltd | Anti-glypican 3 antibody |
MX2007004593A (en) | 2004-10-26 | 2007-06-22 | Chugai Pharmaceutical Co Ltd | Anti-glypican 3 antibody having modified sugar chain. |
US20070087005A1 (en) | 2005-10-14 | 2007-04-19 | Lazar Gregory A | Anti-glypican-3 antibody |
CN101970497B (en) | 2007-04-04 | 2017-05-10 | 希格马托制药工业公司 | Anti-epcam antibody and uses thereof |
ME02345B (en) | 2007-07-17 | 2016-08-31 | Squibb & Sons Llc | Monoclonal antibodies against glypican-3 |
GB0909904D0 (en) | 2009-06-09 | 2009-07-22 | Affitech As | Product |
JP5934099B2 (en) | 2009-10-01 | 2016-06-15 | アメリカ合衆国 | Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptor and its use for the treatment of cancer |
TW201125583A (en) | 2009-12-23 | 2011-08-01 | Bioalliance Cv | Anti-EpCAM antibodies that induce apoptosis of cancer cells and methods using same |
ES2754394T3 (en) | 2010-09-08 | 2020-04-17 | Chemotherapeutisches Forschungsinstitut Georg Speyer Haus | Chimeric antigen receptors with an optimized hinge region |
CN105968209B (en) | 2011-04-19 | 2021-08-03 | 美国政府(由卫生和人类服务部的部长所代表) | Human monoclonal antibodies specific for glypican 3 and uses thereof |
WO2012153186A2 (en) | 2011-05-06 | 2012-11-15 | Kalgene Pharmaceuticals Inc. | Monoclonal antibodies to epcam-icd and methods for detecting epithelial cancer cells |
WO2013070468A1 (en) | 2011-11-08 | 2013-05-16 | The Trustees Of The University Of Pennsylvania | Glypican-3-specific antibody and uses thereof |
US9187558B2 (en) | 2012-03-02 | 2015-11-17 | Academia Sinica | Anti-epithelial cell adhesion molecule (EpCAM) antibodies and methods of use thereof |
WO2013174783A1 (en) | 2012-05-23 | 2013-11-28 | Pieris Ag | Lipocalin muteins with binding-affinity for glypican-3 (gpc-3) and use of lipocalin muteins for target-specific delivery to cells expressing gpc-3 |
WO2013181543A1 (en) | 2012-06-01 | 2013-12-05 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | High-affinity monoclonal antibodies to glypican-3 and use thereof |
CN104140974B (en) | 2013-05-08 | 2017-09-29 | 科济生物医药(上海)有限公司 | Encode the nucleic acid of the Chimeric antigen receptor albumen of GPC 3 and express the T lymphocytes of the Chimeric antigen receptor albumen of GPC 3 |
MX2016004239A (en) | 2013-10-02 | 2016-11-14 | Viventia Bio Inc | Anti-epcam antibodies and methods of use. |
ES2939760T3 (en) * | 2014-03-15 | 2023-04-26 | Novartis Ag | Cancer treatment using a chimeric receptor for antigens |
ES2857226T3 (en) * | 2014-03-15 | 2021-09-28 | Novartis Ag | Regulable chimeric antigen receptor |
JP6831777B2 (en) * | 2014-07-21 | 2021-02-17 | ノバルティス アーゲー | Treatment of cancer using the CD33 chimeric antigen receptor |
US10174095B2 (en) * | 2014-07-21 | 2019-01-08 | Novartis Ag | Nucleic acid encoding a humanized anti-BCMA chimeric antigen receptor |
ES2781175T3 (en) * | 2014-07-31 | 2020-08-31 | Novartis Ag | Optimized subset of T cells containing a chimeric antigen receptor |
CA2958553A1 (en) * | 2014-08-19 | 2016-02-25 | Novartis Ag | Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment |
US10093746B2 (en) | 2014-09-04 | 2018-10-09 | The Trustees Of The University Of Pennsylvania | Glypican-3 antibody and uses thereof |
EP3198010B1 (en) | 2014-09-26 | 2020-11-04 | Baylor College of Medicine | Glypican-3 specific chimeric antigen receptors for adoptive immunotherapy |
WO2016115482A1 (en) * | 2015-01-16 | 2016-07-21 | Novartis Pharma Ag | Phosphoglycerate kinase 1 (pgk) promoters and methods of use for expressing chimeric antigen receptor |
-
2017
- 2017-07-24 AU AU2017301826A patent/AU2017301826A1/en not_active Abandoned
- 2017-07-24 WO PCT/EP2017/068654 patent/WO2018019772A1/en active Search and Examination
- 2017-07-24 EP EP17749637.9A patent/EP3490589A1/en not_active Withdrawn
- 2017-07-24 CN CN201780059507.6A patent/CN110035768A/en active Pending
- 2017-07-24 SG SG11201900634VA patent/SG11201900634VA/en unknown
- 2017-07-24 JP JP2019504106A patent/JP2019530431A/en not_active Withdrawn
- 2017-07-24 KR KR1020197004478A patent/KR20190038567A/en not_active Application Discontinuation
- 2017-07-24 US US16/320,055 patent/US20190262397A1/en not_active Abandoned
- 2017-07-24 CA CA3031846A patent/CA3031846A1/en not_active Abandoned
- 2017-07-25 TW TW106124862A patent/TW201806969A/en unknown
Also Published As
Publication number | Publication date |
---|---|
US20190262397A1 (en) | 2019-08-29 |
JP2019530431A (en) | 2019-10-24 |
CA3031846A1 (en) | 2018-02-01 |
KR20190038567A (en) | 2019-04-08 |
CN110035768A (en) | 2019-07-19 |
WO2018019772A1 (en) | 2018-02-01 |
EP3490589A1 (en) | 2019-06-05 |
TW201806969A (en) | 2018-03-01 |
AU2017301826A1 (en) | 2019-03-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201900634VA (en) | Chimeric antigen receptor | |
SG11201910027YA (en) | Bispecific antibody against ox40 and ctla-4 | |
SG11201807252QA (en) | Anti-lag-3 antibodies | |
SG11201809857TA (en) | Anti-CTLA-4 Antibodies | |
SG11201909949XA (en) | Targeted immunotolerance | |
SG11201811184UA (en) | Lag -3 binding members | |
SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
SG11201805493YA (en) | Binding members with altered diversity scaffold domains | |
SG11201909541WA (en) | Chimeric antibody/t-cell receptor constructs and uses thereof | |
SG11201805422WA (en) | Multivalent and multispecific ox40-binding fusion proteins | |
SG11201908088RA (en) | Antibodies against pd-l1 | |
SG11202000105QA (en) | Anti-cd166 antibodies and uses thereof | |
SG11201805532XA (en) | Multivalent and multispecific 41bb-binding fusion proteins | |
SG11201906552WA (en) | TGF-ß DECOY RECEPTOR | |
SG11201804673WA (en) | Novel anti-claudin antibodies and methods of use | |
SG11201807474SA (en) | Compositions comprising coformulation of anti-pd-l1 and anti-ctla-4 antibodies | |
SG11201805950UA (en) | Self-assembled nanostructures and separation membranes comprising aquaporin water channels and methods of making and using them | |
SG11201803703UA (en) | Anti-complement factor c1q fab fragments and uses thereof | |
SG11201810525XA (en) | Anti-gitr antibodies and uses thereof | |
SG11201805149XA (en) | Compositions comprising 15-hepe and methods of using the same | |
SG11201908056QA (en) | Anti-par2 antibodies and uses thereof | |
SG11201804856VA (en) | C-terminal lysine conjugated immunoglobulins | |
SG11201809374VA (en) | Cd40l-fc fusion polypeptides and methods of use thereof | |
SG11201803975SA (en) | Improved tnf binders | |
SG11201908472VA (en) | Compositions and methods for activating nk cells |